Sugi Predict

Sugi Predict / Targets / PRPF4

PRPF4

U4/U6 small nuclear ribonucleoprotein Prp4 · O43172 · PRPF4 on Sugi Atlas →

1,893 patent compounds predicted against PRPF4, 1,676 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980893 SCHEMBL15980893 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20

Clinical trials — most relevant to PRPF4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy PHASE1/PHASE2ACTIVE_NOT_RECRUITING
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) PHASE1COMPLETED
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects PHASE1COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy nanACTIVE_NOT_RECRUITING
Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Genetic Investigation of Cancer Predisposition nanNOT_YET_RECRUITING
Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) nanRECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes nanRECRUITING
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study nanRECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Study of Constitutional Platelet Disease nanUNKNOWN
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders nanCOMPLETED
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) nanCOMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma nanCOMPLETED
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC nanUNKNOWN
Longitudinal Study of Neurogenetic Disorders nanRECRUITING
Natural History Study for Patients With Nemaline Myopathy in the UK nanACTIVE_NOT_RECRUITING
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
International PPB/DICER1 Registry nanRECRUITING
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients nanRECRUITING
CADASIL Disease Discovery nanCOMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PRPF4 binder may also engage these)

ProteinNameSimilarity
Q9DAW6 — 1.000 Q9DAW6 →
Q5NVD0 — 1.000 Q5NVD0 →
Q3MHE2 — 1.000 Q3MHE2 →
B5FZ19 — 0.977 B5FZ19 →
Q9Z1Z2 — 0.976 Q9Z1Z2 →
Q5XIG8 — 0.975 Q5XIG8 →
Q5ZL33 — 0.973 Q5ZL33 →
Q5RAC9 — 0.973 Q5RAC9 →
Q676U5 — 0.973 Q676U5 →
Q5R7R2 — 0.973 Q5R7R2 →
STRAP Serine-threonine kinase receptor-associated protein 0.970 landscape →
B0BNA7 — 0.968 B0BNA7 →
Q5E959 — 0.968 Q5E959 →
Q9AV81 — 0.968 Q9AV81 →
C4Q0P6 — 0.968 C4Q0P6 →
Q7KNS3 — 0.967 Q7KNS3 →
Q9QZD9 — 0.967 Q9QZD9 →
B4KT48 — 0.967 B4KT48 →
Q8C0J2 — 0.966 Q8C0J2 →
D1ZEB4 — 0.966 D1ZEB4 →
EIF3I Eukaryotic translation initiation factor 3 subunit I 0.965 landscape →
Q6H8D6 — 0.965 Q6H8D6 →
P41318 — 0.965 P41318 →
B6QC56 — 0.965 B6QC56 →
B2AEZ5 — 0.965 B2AEZ5 →
Q96J01 — 0.964 Q96J01 →
Q5E966 — 0.964 Q5E966 →
Q9AYE4 — 0.964 Q9AYE4 →
C5PFX0 — 0.964 C5PFX0 →
Q38884 — 0.964 Q38884 →